FDA Warning Letter Explorer
Drugs · Letter issue date: Feb 24, 2022

Accu Bio-Chem Laboratories

5 extracted findings · 3 model-assigned issue types

FDA source excerpt, selected passage

Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Investigations & OOS21 CFR 211.192

The firm failed to adequately investigate out-of-specification (OOS) results. Specifically, they prepared new test preparations of original samples for multiple OTC drug products with OOS assay results without first investigating the initial failing result. Their OOS procedure lacked appropriate instructions for determining root cause and allowed laboratory personnel to perform actions without scientific justification.

Supporting FDA text
Source excerpt · automated text-match check

Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).

Laboratory controls & testing21 CFR 211.165(e)

The firm failed to perform method verification to ensure that chemical and microbiological test methods were suitable for their intended use. They used the same assay method for the active ingredient in different drug products with varying formulations and used compendial test methods for microorganisms without verifying suitability for each drug product.

Supporting FDA text
Source excerpt · automated text-match check

Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).

Records & data integrity21 CFR 211.68(b)

The electronic data systems used to generate drug product results lacked appropriate controls. Electronic data files from the system used for identity testing could be deleted, and the system controlling high-performance liquid chromatography and gas chromatography did not have all audit trails enabled to record significant changes.

Supporting FDA text
Source excerpt · automated text-match check

Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).
02
Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).
03
You failed to perform method verification to ensure that the chemical and microbiological test methods used to analyze OTC drug products were suitable for their intended use. For example, you used the same assay test method for the active ingredient **(b)(4)** in different drug products of varying formulations. You also tested various drug products for the presence of microorganisms using compendial test methods without verifying the suitability of the methods for each drug product.
04
Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).
05
Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.

What FDA requested

Model-assisted summary. Consult the letter for complete requests and conditions.

  • A retrospective, independent review of all invalidated OOS (including release and stability testing) results for drug product testing conducted for the last three years and a report summarizing the findings of the analysis, including the following for each OOS: determine whether the scientific justification and evidence relating to all invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error; for investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation; for all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include notifications sent to the client.
  • A comprehensive and remediation plan for your OOS result investigation systems. The corrective action and preventive action (CAPA) should include, but not be limited to, addressing the following: quality unit oversight of laboratory investigations; identification of adverse laboratory control trends; resolution of causes of laboratory variation; adequately scoping of each investigation and its CAPA; revised OOS investigation procedures with these and other remediations.
  • A comprehensive independent assessment of your chemical and microbiological drug test methods to determine the suitability of the method (i.e., method verification or method validation when performing analysis for clients). If verification or validation is needed, provide a plan and timeline for completion of the appropriate activity and commitment that you will notify your clients of the outcome.
  • Updated procedures documenting how the suitability of all testing methods will be determined, when method verification and validation occur, and corresponding training records.
  • A complete assessment of documentation systems (paper and electronic) used throughout your laboratory testing operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.
  • Your action plan with timelines to enable audit trails for all applicable electronic laboratory data systems. Also describe your interim controls and specify when procedures will be implemented for the review of all audit trails.

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.